Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Interstitial lung disease: new challenges and evolving phenotypes

V. Cottin
European Respiratory Review 2010 19: 91-93; DOI: 10.1183/09059180.00003910
V. Cottin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

There have been major changes in the field of interstitial lung disease (ILD) in the past decade, mostly in disease classification and diagnostic processes, and in the role of high-resolution computed tomography (HRCT) of the chest in assessment of diagnosis and prognosis. In the present issue of the European Respiratory Review, Harari and Caminati [1] review the current evidence related to ILD. This editorial emphasises some of the most important challenges in idiopathic pulmonary fibrosis (IPF) as well as some of the recent and changing concepts among the many phenotypes of ILD.

CURRENT CHALLENGES IN IPF

IPF is the most severe of the chronic ILDs. One major advance has been made by the better delineating of the disease and the well-adopted international definition of IPF that allowed large clinical trials to be conducted. As some inconsistencies remain in the classification of the idiopathic interstitial pneumonias, an international collaborative task force has begun working under the auspices of the American Thoracic Society and the European Respiratory Society on a possible revision of the current classification. Among many other issues, the task force will have to address the still ongoing debate of usual interstitial pneumonia versus nonspecific pneumonia and their frequently overlapping features; the recently individualised syndrome of combined pulmonary fibrosis and emphysema [2]; and new histopathological patterns that might correspond to clinically relevant entities (e.g. acute fibrinous and organising pneumonia, smoking-related interstitial fibrosis [3], etc.) [4]; and will question the adequacy of maintaining, in the group of idiopathic interstitial pneumonias, entities that are mostly due to environmental exposure or tobacco smoking and therefore not idiopathic (e.g. desquamative interstitial pneumonia) or that are characterised by prominent alveolar, rather than interstitial, changes in histopathology (e.g. organising pneumonia).

Several messages emerge from the review by Harari and Caminati [1] regarding the epidemiology of IPF. First, the incidence, prevalence, and specific mortality of IPF seem to have increased in recent years [5]. Secondly, much remains to be learned about the relative contribution of tobacco smoking, genetic predisposition, cardiovascular disease or risk factors, and IPF. For example, the relative risk of developing acute coronary syndrome or deep vein thrombosis is increased in IPF [6], as may be the risk of obstructive sleep apnoea [7].

Pulmonary physicians will also remember practical messages, such as the importance of considering the age of the patient, in the diagnostic approach of ILD. While the median age of IPF may be frequently underestimated (the mean age is ∼65 yrs in large clinical trials or series [8], yet the peak incidence of IPF occurs between 75 and 85 yrs of age in epidemiological studies [5]). Bronchoalveolar lavage only modestly contributes to the differential diagnosis between IPF and nonspecific interstitial pneumonia [9, 10], but its importance in the process of diagnosing ILDs at large is well established.

Updated guidelines on the management of IPF have been presented at the 2009 Annual Congress of the European Respiratory Society. Although no therapy has yet proven clinically useful in this devastating disease, ongoing and future trials carry significant hope. Controlling the progression of IPF may require the use of combined therapy, as in other areas, including cancer [11], infection with HIV or tuberculosis. It is hoped that future progress made in the drug therapy of IPF will also impact the management of many other chronic diseases that encompass progressive fibrosis or that involve similar processes, such as deregulation of myofibroblast recruitment or cell proliferation.

Two main challenges in IPF are related to situations that significantly contribute to the mortality of this devastating disease, namely acute exacerbations of disease [12] and severe pulmonary hypertension [13]. The former is defined by the rapid deterioration of IPF during the course of disease that cannot be attributed to an identified cause. The recent international consensus statement [14] will undoubtedly boost research developments regarding pathophysiology and management of this severe event. While many groups empirically use corticosteroids and often immunosuppressive therapy, this approach is not yet supported by evidence, and clinical research is eagerly needed. Other conditions characterised by rapid progression of disease but not fulfilling the definition of acute exacerbations, coined accelerated disease or subacute exacerbation of IPF, also need further evaluation.

Pulmonary hypertension confirmed by right heart catheterisation is present in more than one-third of patients with IPF referred for lung transplantation, and significantly affects mortality, with a 1-yr mortality of 28% in patients with pulmonary hypertension compared with 5% in its absence [15]. Whether specific therapy of pulmonary hypertension may impact the outcome is currently investigated in observational studies and clinical trials.

Although it has not translated into effective therapy, much progress has been made in the understanding of fibrogenesis in recent years. The various origins of fibroblasts in the fibrotic lung (resident lung fibroblasts, epithelial lung cells through epithelial mesenchymal differentiation and circulating progenitors known as fibrocytes, which might be used as biomarkers of active fibrosis in the future) is the subject of active research, as this may give new insights into novel therapies. Genomic studies have showed that the gene expression profile of IPF differs from that of diseases where significant inflammation is found, such as hypersensitivity pneumonitis [16]. Many of the genes with increased expression in IPF encode proteins associated with extracellular matrix formation, cell proliferation, migration, invasion and cell morphology, and proteins expressed in smooth muscle cells [17], reminiscent of that observed in cancer biology [11]. This observation holds true in studies on lungs obtained from patients with the accelerated variant of IPF [18] or acute exacerbation of IPF [19]. It is not clear whether activation of inflammation pathways is not key to the pathogenesis of IPF, or if published genomic studies reflected prominent remodelling in the fibrotic lung while failing to catch more subtle deregulation of other pathways involved in the interplay between injured pneumocytes and myofibroblasts.

EVOLVING PHENOTYPES OF ILD

Several phenotypes of ILD are being increasingly recognised that progressively modify the clinical approach and patients' care.

The entity of combined pulmonary fibrosis and emphysema has been classified in the group of smoking-induced chronic lung disease [2, 20]. It is characterised by the association of distinct features, including tobacco smoking, severe dyspnoea, unexpected subnormal spirometry, severely impaired transfer capacity for carbon monoxide, hypoxaemia on exercise and characteristic imaging features. Although the pathophysiology of this condition is not well understood, the causative role of tobacco smoking is obvious. Diagnosing this syndrome has clinical relevance, because it carries an increased risk of developing pulmonary hypertension with increased mortality [21, 22].

ILD associated with connective tissue disease is a complex field [23] that can be viewed as a model of pulmonary fibrosis with a known aetiological context. Survival in patients with ILD associated with connective tissue disease is better than that of IPF [24]. Studies concerned with the determinants of long-term prognosis are emerging [25]; for example, the pattern on HRCT or the extent of ILD on HRCT are predictive of survival in patients with systemic sclerosis or rheumatoid arthritis, respectively [26, 27]. Differentiating IPF from occult or undifferentiated connective tissue disease is a recurring question in clinical care, with frequent therapeutic consequences, especially in patients with a histological pattern of nonspecific interstitial pneumonia. “Idiopathic” nonspecific interstitial pneumonia may thus in some cases correspond to formes frustes of connective tissue disease limited to the lung [28], hence the recently proposed terminology of “lung-dominant connective tissue disease” to qualify this condition [29]. Furthermore, the ILD may be the presenting manifestation of the connective tissue disease in a patient with yet-to-come extra-respiratory manifestations; this has been described most widely in patients with nonspecific interstitial pneumonia, but also in those with organising pneumonia, as reported in this issue of the European Respiratory Review [30].

The role of auto-antibodies needs clarification. Although circulating auto-antibodies are frequently found in patients with interstitial pneumonia and subtle or no extra-thoracic manifestations, the survival of patients with IPF is not altered by the presence of auto-antibodies [31]. Several studies have reported the presence of anti-neutrophil cytoplasmic antibodies in patients with pulmonary fibrosis; however, the clinical relevance of this observation is incompletely known. Systemic vasculitis and, particularly, microscopic polyangiitis have been observed during the follow-up of patients with IPF who had anti-neutrophil cytoplasmic antibodies [32].

Many other recent developments in ILD that cannot be mentioned here are analysed in depth in the review article by Harari and Caminati [1]. For example, the first international guidelines on lymphangioleiomyomatosis [33] cover all aspects of diagnostic and therapeutic management of this orphan disease and will undoubtedly facilitate multicentre clinical trials and stimulate collaborative studies, as it has been the case in IPF.

Statement of interest

V. Cottin has participated as a member of a steering committee, member of a data monitoring committee, member of an adjudication committee and investigator in clinical trials sponsored by Actelion, Boehringer, Centocor, Intermune and Wyeth, and has been a lecturer for Actelion.

Provenance

Submitted article, peer reviewed.

  • Received April 7, 2010.
  • Accepted April 7, 2010.
  • © ERS

References

  1. ↵
    Harari S, Caminati A. Update on diffuse parenchymal lung disease. Eur Respir Rev 2010; 19: 97–108.
    OpenUrlCrossRefPubMed
  2. ↵
    Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586–593.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Katzenstein AL, Mukhopadhyay S, Zanardi C, et al. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010; 41: 316–325.
    OpenUrlCrossRefPubMed
  4. ↵
    du Bois R, King TE Jr. Challenges in pulmonary fibrosis ×5: the NSIP/UIP debate. Thorax 2007; 62: 1008–1012.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257–1261.
    OpenUrlCrossRefPubMed
  7. ↵
    Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136: 772–778.
    OpenUrlCrossRefPubMed
  8. ↵
    King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 75–81.
    OpenUrlCrossRefPubMed
  9. ↵
    Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22: 239–244.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043–1047.
    OpenUrlCrossRefPubMed
  11. ↵
    Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496–504.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 2008; 32: 170–174.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31: 1357–1367.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636–643.
    OpenUrlCrossRefPubMed
  15. ↵
    Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–752.
    OpenUrlCrossRefPubMed
  16. ↵
    Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188–198.
    OpenUrlCrossRefPubMed
  17. ↵
    Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009; 4: e5134.
    OpenUrlCrossRefPubMed
  18. ↵
    Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007; 2: e482.
    OpenUrlCrossRefPubMed
  19. ↵
    Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167–175.
    OpenUrlCrossRefPubMed
  20. ↵
    Balbi B, Cottin V, Singh S, et al. Smoking-related lung diseases: a clinical perspective. Eur Respir J 2010; 35: 231–233.
    OpenUrlFREE Full Text
  21. ↵
    Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10–15.
    OpenUrlCrossRefPubMed
  22. ↵
    Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35: 105–111.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33: 882–896.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705–711.
    OpenUrlCrossRefPubMed
  25. ↵
    Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010; 35: 112–117.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322–1328.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254.
    OpenUrlCrossRefPubMed
  28. ↵
    Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 2007; 176: 691–697.
    OpenUrlCrossRefPubMed
  29. ↵
    Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010; (in press)
  30. ↵
    Henriet AC, Diot E, Marchand-Adam S, et al. Organising pneumonia can be the inaugural manifestation in connective tissue diseases, including Sjögren's syndrome. Eur Respir Rev 2010; 19: 161–163.
    OpenUrlPubMed
  31. ↵
    Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136: 23–30.
    OpenUrlCrossRefPubMed
  32. ↵
    Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008; 102: 1392–1398.
    OpenUrlCrossRefPubMed
  33. ↵
    Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14–26.
    OpenUrlFREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 19 Issue 116 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interstitial lung disease: new challenges and evolving phenotypes
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Interstitial lung disease: new challenges and evolving phenotypes
V. Cottin
European Respiratory Review Jun 2010, 19 (116) 91-93; DOI: 10.1183/09059180.00003910

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Interstitial lung disease: new challenges and evolving phenotypes
V. Cottin
European Respiratory Review Jun 2010, 19 (116) 91-93; DOI: 10.1183/09059180.00003910
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • CURRENT CHALLENGES IN IPF
    • EVOLVING PHENOTYPES OF ILD
    • Statement of interest
    • Provenance
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Insights into acute and chronic respiratory failure: highlights of RFMV 2022
  • Nonpharmacological interventions in COPD
  • The flare of care for rare: per aspera ad astra for rare lung diseases!
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society